4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Ipsen S.A. (IPN) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Paris, France with about 5,535 employees. Its market capitalization is roughly €13 billion. In the fiscal year ended 2025-12-31, IPN reported €3.9B in revenue and €444M in net income.
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience in North America, Europe, and internationally.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | €3.9B | €3.6B | €3.3B | €3.2B | — |
| Gross Profit | €3.2B | €2.9B | €2.7B | €2.6B | — |
| Operating Income (EBIT) | €945M | €688M | €611M | €871M | — |
| Net Income | €444M | €346M | €644M | €649M | — |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Dividends Paid | (€116M) | (€100M) | (€100M) | (€99M) | — |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | €6.9B | €6.4B | €6.3B | €5.6B | — |
| Total Liabilities | €2.6B | €2.3B | €2.5B | €2.3B | — |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive IPN viewer.
About TickerBase · Data methodology & sources · Privacy · Terms